Fortress Biotech (NASDAQ:FBIO) is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.
Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies. Its affiliates include companies developing immuno‐oncology therapies, gene and cell therapy approaches for genetic and rare disorders, as well as topical and systemic dermatology products. By leveraging internal expertise and external partnerships, the company seeks to optimize trial design, regulatory strategy and commercialization pathways for each candidate, aiming to accelerate time to market and enhance value creation.
Founded in 2007 by Pablo Legorreta, Fortress Biotech completed its initial public offering under the name Coronado Biosciences before rebranding to its current identity in 2016. Over more than a decade, the company has cultivated relationships with leading academic institutions, contract research organizations and commercial partners to support global clinical development and eventual product launches. While its primary operations are based in the United States, Fortress Biotech’s programs often involve international trial sites and regulatory filings across North America and Europe.
Under the leadership of Chairman and Chief Executive Officer Pablo Legorreta, Fortress Biotech maintains a strategic focus on unlocking the potential of under‐resourced programs. By structuring development efforts through dedicated subsidiaries, the company aims to balance risk and reward, fostering innovation across multiple therapeutic areas while preserving the flexibility to collaborate with larger pharmaceutical and biotechnology firms.
